ANNX — Annexon, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1528115 ·
Last close
$3.64
Market Cap
$690.07M
52W High
$7.18
52W Low
$2.54
ADV30
2,878,343
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -57,227,000 | -55,348,000 | 246,068,000 | 199,270,000 | 60,007,000 |
| Mar 2026 | 0 | — | -46,053,000 | -44,142,000 | 262,888,000 | 175,208,000 | 58,355,000 |
| Dec 2025 | 0 | — | -50,258,000 | -48,256,000 | 277,571,000 | 162,051,000 | 65,923,000 |
| Sep 2025 | 0 | — | -57,018,000 | -54,922,000 | 229,142,000 | 139,419,000 | 67,700,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-183,097,000
Investing CF
$119,488,000
Financing CF
$141,692,000
CapEx
$-143,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.22
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-961,531,000
Inventory
—
Receivables
—
ST Investments
$49,817,000
EBIT TTM
$-205,055,000
Pretax Income TTM
$-196,476,000
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -216,407,000 | -206,690,000 | 277,571,000 | 65,923,000 | 211,648,000 | -186,356,000 |
| Dec 2024 | 0 | -154,073,000 | -138,200,000 | 350,071,000 | 56,966,000 | 293,105,000 | -118,006,000 |
| Dec 2023 | 0 | -143,723,000 | -134,237,000 | 297,674,000 | 47,118,000 | 250,556,000 | -121,142,000 |
| Dec 2022 | 0 | -145,599,000 | -141,947,000 | 285,096,000 | 53,902,000 | 231,194,000 | -116,309,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.08
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $4.00 · spot: $3.64 · call volume: 87 · put volume: 2,511
Expected Move to 2026-12-18:
±$2.94
(80.77%) —
implied range
$0.70 –
$6.58
· ATM straddle on $4.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SLN | Silence Therapeutics plc | $694.88M | $11.18 | — |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $682.44M | $4.13 | — |
| COLL | COLLEGIUM PHARMACEUTICAL, INC | $698.41M | $22.53 | — |
| VSTM | Verastem, Inc. | $700.96M | $7.74 | — |
| CLYM | Climb Bio, Inc. | $669.71M | $11.66 | — |
News headlines (Yahoo Finance, 1h cache)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
2026-09-16 20:05 · Yahoo
Annexon to Participate in Upcoming September Investor Conferences
2026-09-02 12:00 · Yahoo
What Annexon (ANNX)'s Dual-Endpoint ARCHER II Update Means For Shareholders
2026-08-24 08:08 · Yahoo
Annexon (ANNX), What Is Behind Its Latest Update?
2026-08-13 18:13 · Yahoo
Annexon shares fall as second-quarter loss exceeds Wall Street forecasts
2026-08-12 11:33 · Yahoo
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
2026-08-06 12:00 · Yahoo
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
2026-07-30 20:01 · Yahoo
How Investors Are Reacting To Annexon (ANNX) Phase 3 Tanruprubart Win And Vonaprument Updates
2026-07-16 23:17 · Yahoo
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
2026-07-14 20:05 · Yahoo
Annexon, Inc. Q2 2026 Earnings Call Summary
2026-08-12 20:56 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-09-25 16:15:13 | 2026-09-24 | Love Douglas | Pres, CEO | P - Purchase | 3.83 | 26065 | 99829 |